Standard-dose tenecteplase (TNKase) beat low-dose alteplase as a bridge to stroke thrombectomy in bleeding-prone patients, a Japanese trial found. Early reperfusion outcomes significantly favored ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results